蛋白质聚合及其在神经退行性疾病中的影响机制
Junyun Wu1, Jianan Wu2, Tao Chen1
1Neuroscience Care Unit, Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang, 310009, China.
Neurochemistry international
|October 13, 2024
概括
蛋白质聚合,神经退行性疾病 (NDs) 的标志,涉及像粉样蛋白β,Tau,α-Synuclein和TDP-43.3这样的蛋白质. 破坏蛋白质平衡的因素驱动聚合,为NDs提供治疗点.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 生物化学 生化学
背景情况:
- 蛋白质聚合是神经退行性疾病 (NDs) 的关键病理特征.
- 特定的蛋白质聚合物如粉样蛋白β (Aβ),Tau,α-Synuclein (α-Syn) 和TDP-43都与阿尔茨海默病,帕金森病,ALS和相关痴呆症有关.
- 在个别的ND病例中观察到多种蛋白质病理的同时发生,这表明了复杂的相互作用.
研究的目的:
- 审查各种NDs中蛋白质聚合的病理基础.
- 探索同一疾病内的不同蛋白质病理之间的相互联系.
- 检查各种因素如何影响蛋白质聚合,并确定潜在的治疗策略.
主要方法:
- 关于神经退行性疾病中的蛋白质聚合研究的文献综述.
- 分析不同蛋白质病理 (Aβ,Tau,α-Syn,TDP-43) 之间的相互作用.
- 研究调节蛋白质聚合的因素,包括蛋白质稳态,细胞环境和遗传因素.
主要成果:
- 蛋白质聚合是主要的NDs病理学的核心.
- Aβ,Tau,α-Synuclein和TDP-43之间的相互作用有助于疾病的复杂性.
- 蛋白质稳态,细胞环境,金属离子,PTM和遗传学的破坏会影响聚合.
结论:
- 了解蛋白质聚合和蛋白质间通信的机制对于NDs至关重要.
- 针对调节蛋白质聚合的因素为神经退行性疾病提供了有前途的治疗途径.
相关概念视频
03:03Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
01:26Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
01:15Parkinson's Disease: Overview
487
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
487
01:13The Proteasome
816
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
816
01:22Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166